Atheric Pharmaceutical LLC is providing solutions for Zika

Some of our Zika Response Working Group members have started a new company called Atheric Pharmaceutical LLC. Atheric Pharmaceutical LLC ("Atheric(tm)") is a biopharmaceutical company focused on the rapid development and commercialization of re-purposed drugs to prevent and treat Zika as well as Flavivirus disease.   Atheric(tm)'s lead drug products, Hydroxychloroquine and Amodiaquine, are reformulated broad spectrum 4-Aminoquinoline-class antiviral drugs that inhibit autophagy-dependent viral replication.  Atheric is committed to providing broad-spectrum medical countermeasures for Zika and other neglected tropical diseases.  Provisional patents covering the used of these compounds for Zika and other Flaviviruses have been filed with the US Patent and Trademark Office.  Clinical trials to determine correct dosing and proprietary formulations appropriate for the indicated therapies are being rapidly developed.  Regulatory discussions with FDA have been initiated. 

ANTI-VIRAL ZIKA VIRUS DRUGS

Zika outbreak medical countermeasure (MCM) strategies have been identified, with the most promising MCM available for expedited clinical testing identified being re-purposed anti-malarial drugs  Of these, the most suitable for immediate clinical testing for use in protecting against the Zika Virus infection; to prevent development of Zika Virus fetal syndrome and GBS have been identified.  Provisional patents covering the used of these compounds for Zika and other Flaviviruses have been filed with the US Patent and Trademark Office.  Clinical trials to determine correct dosing and proprietary formulations appropriate for the indicated therapies are being rapidly developed.  Regulatory discussions with FDA have been initiated. 

Zika virus has been postulated as playing a key role in the pathogenesis of Zika-associated primary microcephaly and GBS.  The anti-malarial drugs under pending patents are autophagy inhibitors, and in vitro testing has demonstrated efficacy.  Of interest is that these drugs have been safely used during pregnancy, and cross the placenta enabling clinically significant pharmacodistribution to both mother and fetus.  Systemic literature review with meta- analysis indicates that prenatal exposure to these drugs during maternal autoimmune disease treatment does not appear to increase the risk of adverse pregnancy outcomes, except those associated with the underlying disease.

Jill Malone